Merck Ventures, which previously led a seed round in 2015, has returned to lead a series A round that featured fellow existing shareholder Novo Seeds.
Switzerland-based biopharmaceutical firm Inthera Bioscience closed a SFr10.5m ($11m) series A round on Wednesday led by Merck Ventures, the corporate venturing arm of pharmaceutical company Merck.
The round included Novo Seeds, the early-stage investment arm of pharmaceutical group Novo, and Aglaia Biomedical Ventures as well as an unnamed private investor.
Founded in 2013, Inthera Bioscience is working on drugs to treat solid tumours. The company currently has several programs in pre-clinical development.
Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez…
